Surgical treatment of the thyroid nodes of uncertain cytological structure
Objective. To determine the clinical factors of the enhanced risk of malignancy in patients, having categories of cytological conclusions III (AUS/FLUS) and IV (FN/SFN).
Маterials and methods. There were 11 621 patients examined with cytological investigation of thyroidal nodes under ultrasonographic control. Cytological conclusions of category ІІІ (AUS/FLUS) have characterized 621 nodes, while conclusions of category IV (FN/SFN) - 1215 nodes. There were operated 150 patients, owing cytological conclusions of category III, 436 patients - with cytological conclusions of category IV, and 11 patients, having categories of cytological conclusions III and IV.
Results. Papillary and follicular carcinomas were revealed in 36% patients, suffering thyroidal nodes of the Bethesda III category, what is trustworthily more frequently (р < 0.01), than in the patients, suffering thyroidal nodes of the Bethesda category IV (25.1%).
There were revealed such factors of risk for malignant properties in patients, suffering thyroidal nodes with the Bethesda category III, as: the node size 2 сm and less, its hypoechogeneicity, uneven borders, irregular form, and presence of hyperechogenic foci (р < 0.01). Cystic degeneration of a node constitutes the sign of its benign origin (р < 0.01).
Conclusion. High risk of malignant changes (36%) in thyroidal nodes, in accordance to cytological conclusion of the Bethesda category III revealed, trusts the need for enhanced oncological suspicion and conduction of surgical treatment. Тhe additional factors of malignant changes must be taking into account as well, such as the node size 2 сm and less, its hypoechogeneicity, uneven borders, irregular form, and presence of hyperechogenic foci.
Liu X, Medici M, Kwong N, Angell TE, Marqusee E, Kim MI, et al. Bethesda Categorization of Thyroid Nodule Cytology and Prediction of Thyroid Cancer Type and Prognosis. Thyroid. 2016;26(2):256-61. doi: 10.1089/thy.2015.0376.
Mileva M, Stoilovska B, Jovanovska A, Ugrinska A, Petrushevska G, Kostadinova-Kunovska S, et al. Thyroid cancer detection rate and associated risk factors in patients with thyroid nodules classified as Bethesda category III. Radiol Oncol. 2018;52(4):370-6. doi: 10.2478/raon-2018-0039.
Cibas ES, Syed ZA. The Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol 2009; 132:658-665. doi: 10.1309/AJCPPHLWMI3JV4LA.
Evranos B, Polat SB, Baser H, Ozdemir D, Kilicarslan A, Yalcin A, et al. Bethesda classification is a valuable guide for fine needle aspiration reports and highly predictive especially for diagnosing aggressive variants of papillary thyroid carcinoma. Cytopathology. 2017;28(4):259-67. doi: 10.1111/cyt.12384.
Godoi Cavalheiro B, Kober Nogueira Leite A, Luongo de Matos L, Palermo Miazaki A, Marcel Ientile J, Aurelio V Kulcsar M, et al. Malignancy Rates in Thyroid Nodules Classified as Bethesda Categories III and IV: Retrospective Data from a Tertiary Center. Int J Endocrinol Metab. 2017;16(1):e12871. doi: 10.5812/ijem.12871.
Al Dawish MA, Alwin Robert A, Thabet MA, Braham R. Thyroid Nodule Management: Thyroid-Stimulating Hormone, Ultrasound, and Cytological Classification System for Predicting Malignancy. Cancer Inform. 2018;17:1176935118765132. doi: 10.1177/1176935118765132.
Maia FF, Matos PS, Pavin EJ, Zantut-Wittmann DE. Thyroid imaging reporting and data system score combined with Bethesda system for malignancy risk stratification in thyroid nodules with indeterminate results on cytology. Clin Endocrinol (Oxf). 2015;82(3):439-44. doi: 10.1111/cen.12525.
Delfim RLC, Veiga LCGD, Vidal APA, Lopes FPPL, Vaisman M, Teixeira PFDS. Likelihood of malignancy in thyroid nodules according to a proposed Thyroid Imaging Reporting and Data System (TI-RADS) classification merging suspicious and benign ultrasound features. Arch Endocrinol Metab. 2017;61(3):211-21. doi: 10.1590/2359-3997000000262.
Topaloglu O, Baser H, Cuhaci FN, Sungu N, Yalcin A, Ersoy R, Cakir B. Malignancy is associated with microcalcification and higher AP/T ratio in ultrasonography, but not with Hashimoto’s thyroiditis in histopathology in patients with thyroid nodules evaluated as Bethesda Category III (AUS/FLUS) in cytology. Endocrine. 2016;54(1):156-68.
Tarashchenko YN, Kovalenko AE, Bolgov MY, Guda BB, Shelkovoy EA, Nekrasov KA, Mankovskaya O, Kashuba VI. BRAF-status of papillary thyroid carcinomas and strategy of surgical treatment. Klin Khir.2015;(6):49-54 PMID: 26521469. [In Russian].
Nikiforov YE. Role of molecular markers in thyroid nodule management: then and now. Endocr Pract. 2017;23(8):979-88. doi: 10.4158/EP171805.RA.
Voskoboinyk LH. Possibilities of preoperative and intraoperative methods for the diagnosis of thyroid nodules. Mìžnarodnij endokrinologìčnij žurnal. 2018;14(5):528-38. doi: 10.22141/2224-0722.214.171.1248.142692. [In Russian].
Zelinskaya A. Preoperative prognosis of radioiodine-resistance of papillary thyroid cancer. Art of medicine. 2018;(4):78-86. [In Ukrainian].
Zelinskaya A. Possibilities of cytological diagnostics in preoperative prediction of tumor behavior and the choice of adequate therapy. Endocrinology. 2018;23(1):47-53. [In Ukrainian].
This work is licensed under a Creative Commons Attribution 4.0 International License.